New developments in targeted therapy for soft tissue sarcoma.
Soft tissue sarcomas (STS) are rare diseases, with an estimated 10,390 new cases in the United States in 2008. Unfortunately, only 50% are cured with surgical resection. The standard cytotoxic chemotherapeutic agents have not been successful in the treatment of metastatic disease. The standard single-agent chemotherapy for metastatic disease is doxorubicin, with only 20% to 25% response rates. The combination of doxorubicin with other agents, such as ifosfamide, has improved response rates, without any improvement in overall survival. New targeted therapies have shown some activity in STS; however, disease stabilization is seen more often than a true radiographic response. The combination of cytotoxic chemotherapy with more targeted and novel agents may be appropriate to improve outcome in these patients. The agents of interest in sarcomas at this time are multi-tyrosine kinase inhibitors, antiangiogenesis agents, inhibitors of mammalian target of rapamycin, hypoxia-activating prodrugs, insulin growth factor monoclonal antibodies, and tumor necrosis factor-related apoptosis-inducing ligand agonists.
Ganjoo
Kristen N
KN
Stanford University, 269 Campus Drive, Stanford, CA 94305, USA. kganjoo@stanford.edu
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004358:Drug Therapy / Q000379:methods* / Q000639:trends; D000068338:Everolimus; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab; D004317:Doxorubicin; D000068338:Everolimus; D020123:Sirolimus
Nat Rev Cancer. 2003 Oct;3(10):721-32
13130303
Clin Cancer Res. 2009 Sep 1;15(17):5584-90
19690193
Cancer Res. 2007 Mar 15;67(6):2800-8
17363602
Cancer Res. 1999 Aug 1;59(15):3588-91
10446966
Lancet Oncol. 2010 Feb;11(2):129-35
20036194
F1000 Med Rep. 2009 Aug 17;1:
20948718
Clin Cancer Res. 2009 Sep 15;15(18):5910-6
19723647
J Clin Oncol. 2009 Sep 10;27(26):4413-21
19652058
N Engl J Med. 2002 Aug 15;347(7):472-80
12181401
Nature. 2006 May 25;441(7092):437-43
16724055
Br J Cancer. 2001 Apr 20;84(8):1070-5
11308256
Cancer Res. 1997 Dec 1;57(23):5328-35
9393757
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Clin Cancer Res. 2008 Jun 1;14(11):3450-5
18519776
Clin Cancer Res. 1998 Nov;4(11):2647-55
9829727
Clin Cancer Res. 2005 Jan 1;11(1):206-16
15671548
Nat Rev Drug Discov. 2006 Aug;5(8):671-88
16883305
Cell Growth Differ. 2000 Dec;11(12):655-64
11149601
J Clin Oncol. 2005 Oct 1;23(28):7135-42
16192597
Curr Pharm Des. 2007;13(21):2118-28
17627544
Cancer Res. 1996 Mar 1;56(5):941-3
8640781
J Clin Oncol. 2007 Jul 1;25(19):2755-63
17602081
J Clin Oncol. 2002 Jun 15;20(12):2824-31
12065559
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):167-75
17707270